» Articles » PMID: 29997622

Deterioration of Organ Function As a Hallmark in Sepsis: The Cellular Perspective

Overview
Journal Front Immunol
Date 2018 Jul 13
PMID 29997622
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Development of organ dysfunction discriminates sepsis from uncomplicated infection. The paradigm shift implicated by the new sepsis-3 definition holds that initial impairment of any organ can pave the way for multiple organ dysfunction and death. Moreover, the role of the systemic inflammatory response, central element in previous sepsis definitions, has been questioned. Most strikingly, a so far largely underestimated defense mechanism of the host, i.e., "disease tolerance," which aims at maintaining host vitality without reducing pathogen load, has gained increasing attention. Here, we summarize evidence that a dysregulation of critical cellular signaling events, also in non-immune cells, might provide a conceptual framework for sepsis-induced dysfunction of parenchymal organs in the absence of significant cell death. We suggest that key signaling mediators, such as phosphoinositide 3-kinase, mechanistic target of rapamycin, and AMP-activated protein kinase, control the balance of damage and repair processes and thus determine the fate of affected organs and ultimately the host. Therapeutic targeting of these multifunctional signaling mediators requires cell-, tissue-, or organ-specific approaches. These novel strategies might allow stopping the domino-like damage to further organ systems and offer alternatives beyond the currently available strictly supportive therapeutic options.

Citing Articles

Exploiting the Zebrafish Model for Sepsis Research: Insights into Pathophysiology and Therapeutic Potentials.

He J, Xu P, Chen R, Chen M, Wang B, Xie Y Drug Des Devel Ther. 2024; 18:5333-5349.

PMID: 39600867 PMC: 11590671. DOI: 10.2147/DDDT.S500276.


Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19.

Cavaillon J, Chousterman B, Skirecki T J Intensive Med. 2024; 4(3):326-340.

PMID: 39035623 PMC: 11258514. DOI: 10.1016/j.jointm.2024.01.001.


Unraveling the Multifaceted Role of Glutathione in Sepsis: A Comprehensive Review.

Tandon R, Tandon A Cureus. 2024; 16(3):e56896.

PMID: 38659506 PMC: 11042744. DOI: 10.7759/cureus.56896.


Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.

Thomas-Ruddel D, Bauer M, Moita L, Helbig C, Schlattmann P, Ehler J BMJ Open. 2024; 14(4):e075158.

PMID: 38653508 PMC: 11043739. DOI: 10.1136/bmjopen-2023-075158.


Controversies Surrounding Albumin Use in Sepsis: Lessons from Cirrhosis.

Wiedermann C Int J Mol Sci. 2023; 24(24).

PMID: 38139434 PMC: 10743695. DOI: 10.3390/ijms242417606.


References
1.
Medzhitov R . Septic shock: on the importance of being tolerant. Immunity. 2013; 39(5):799-800. DOI: 10.1016/j.immuni.2013.10.012. View

2.
Ayres J, Freitag N, Schneider D . Identification of Drosophila mutants altering defense of and endurance to Listeria monocytogenes infection. Genetics. 2008; 178(3):1807-15. PMC: 2278058. DOI: 10.1534/genetics.107.083782. View

3.
Bruns T, Zimmermann H, Stallmach A . Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol. 2014; 20(10):2542-54. PMC: 3949263. DOI: 10.3748/wjg.v20.i10.2542. View

4.
Ayres J, Schneider D . Tolerance of infections. Annu Rev Immunol. 2012; 30:271-94. DOI: 10.1146/annurev-immunol-020711-075030. View

5.
Raberg L, Sim D, Read A . Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science. 2007; 318(5851):812-4. DOI: 10.1126/science.1148526. View